Kuwait, March 7, 2017. The Heberprot-P Cuban product for the treatment of diabetic foot, recently registered in Kuwait, was launched by the Center for Genetic Engineering and Biotechnology (CIGB) in coordination with the Central Gulf Medical Company Company at the Hotel Mövenpick of this capital.
The launching ceremony was attended by Dr. Eulogio Pimentel Vázquez, General Director of CIGB, who provided an overview of the development of Cuba in the field of biotechnology, those products contribute to the diagnosis, prevention and treatment of many diseases and its Impact on health, agriculture and the environment.
Dr. Jorge Berlanga, creator of Heberprot P and Dr. José Ignacio Fernández Montequín of the Institute of Angiology and Vascular Surgery of Cuba offered extensive information on Heberprot-B, noting that its characteristics and effects make it the only therapeutic alternative for the deep and complex ulcers suffered by diabetics and reduces the risk of limb amputation and the consequences for the patient and his environment.
They noted that this product, developed by the Center for Genetic Engineering and Biotechnology (CIGB) in the mid-1990s, is an injectable formulation that is administered by infiltration, accelerating the healing of deep ulcers, derived from diabetes.
Present at the launching were the Cuban ambassador to Kuwait Andrés González Garrido, Dr. Kazem Behbehani, General Manager of Central Gulf Medical, the local agent , responsible for the promotion, distribution and marketing of Heberport P in Kuwait, Hadel Mustafá Paolini , ambassador of Venezuela in Kuwait, as well as other health professionals from different hospitals and clinics in the country and the group of 10 Cuban nurses who are working in Dasman Diabetes Institute